SPN-817 is under clinical development by Supernus Pharmaceuticals and currently in Phase II for Epilepsy. According to GlobalData, Phase II drugs for Epilepsy have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SPN-817’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SPN-817 overview
SPN-817 (INS-001) is under development for the treatment of complex partial seizures include focal impaired awareness seizures, epileptic encephalopathy, Lennox-Gastaut syndrome, treatment resistant epilepsy and dravet syndrome. The drug candidate is administered by oral route. It is an extended release formulation of synthetic form of huperzine A. The drug candidate targets acetylcholinesterase. It was also under development for Alzheimer's disease, multiple sclerosis and pain.
Supernus Pharmaceuticals overview
Supernus Pharmaceuticals is a specialty pharmaceutical company. It develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company’s neurology portfolio consists of Oxtellar XR (oxcarbazepine), an adjunct therapy for the treatment of partial seizures; Trokendi XR (topiramate), an initial monotherapy in patients with partial-onset of primary generalized tonic-clonic seizures associated with Lennox-Gastaut syndrome; Apokyn, and Xadago for Parkinson’s disease and Myobloc for cervical dystonia and sialorrhea in adults. Its major pipeline products include SPN-830, SPN-817, SPN-443, SPN-446, SPN-448, and SPN-820. The company’s technology platforms include Microtrol (multi-particle delivery platform), Solutrol (matrix delivery platform), and EnSoTrol (osmotic delivery system). The company’s majority customers include pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals is headquartered in Rockville, Maryland, the US.
For a complete picture of SPN-817’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
